English Data Summary
Back to reportsCompany Profile
Shandong Nuominkang Pharmaceutical Research Institute Co., Ltd. is indexed in Shandong under Biomedicine. The table below combines recognition context, peer samples and public references for search and review.
Published 2026-06-14. Use company files, policy notices, patent records and the Chinese source report for original-language verification.
Summary
Shandong Nuominkang Pharmaceutical Research Institute Co., Ltd. is indexed in the China Little Giant company database. The profile is associated with Shandong. The report is grouped under Biomedicine. Recognition context: 2025 7th batch. Chinese source report date: 2026-06-14. 3 source-page links are available on this page or in the Chinese report. The English brief covers company profile, product direction, industry-chain role, patent and R&D signals, scale indicators and policy-material checkpoints, with internal links to the company page, Chinese source report and related topic hubs.
English Data Summary
This is a structured summary of the portal's recorded company fields, not a full English translation of the Chinese report or an independently verified company thesis.
Recorded Company Profile
- Company: Shandong Nuominkang Pharmaceutical Research Institute Co., Ltd.
- Region: Shandong
- Recorded industry: Biomedicine
- Recorded chain position: Biomedicine and medical devices / Complete systems and application scenarios
- Recorded recognition context: 2025 7th batch
- Registered-capital field: RMB 14.81 million
- Employee field: 112 employees
- Listing-status field: Not listed
- Patent-related record count: 58
Industry-chain Context
Industry and chain-position labels describe the portal's database classification. They do not establish a specific production process, client list, competitive advantage or a company's participation in an adjacent sector.
Research Boundary and Original Report
Registration, employee and patent fields retain their recorded database scope; their presence does not establish current capacity, financial performance or ownership of any specific patent. Company-specific products, financial figures, customers and operating claims require the original disclosures. Chinese page provides the corresponding profile and source links. This summary does not constitute investment advice or confirmation of a policy application outcome.
Data Comparison
Peer, chain, region and patent matrices
Core Benchmark
Policy Evidence Matrix
| Evidence item | Current record | Source field | Status |
|---|---|---|---|
| Company identity | Shandong Nuominkang Pharmaceutical Research Institute Co., Ltd. | Company profile | Profile field |
| Recognition batch | 2025 7th batch | Certification record | Source check |
| Product and chain role | Biomedicine and medical devices / Complete systems and application scenarios | Product and chain fields | Profile field |
| Patent and R&D | 50-99 records · R&D detail not published | Patent and R&D fields | Profile field |
| Capital and scale | RMB 14.81 million · 112 employees · Not listed | Capital, employee and listing fields | Profile field |
| Public references | 3 linked references | Reference links | Linked source |
Growth and Filing Signals
- Established2019
- Recognized2025
- Current profile2026
| Signal | Record | Use |
|---|---|---|
| Operating years before recognition | 6 years | Recognition timeline |
| R&D field | R&D detail not published | Company profile |
| Source coverage | 3 linked sources | Report references |
Region and Batch
Regional Recognition Ladder
Batch-level counts show the province, city and industry recognition rhythm around this company.
NationalShandongChinaBiomedicine
| Batch | National | Province | City | Industry |
|---|---|---|---|---|
| 2019 / 1st batch | 248 | 18 | 5 | 32 |
| 2020 / 2nd batch | 1,744 | 81 | 6 | 276 |
| 2021 / 3rd batch | 2,930 | 172 | 10 | 214 |
| 2022 / 4th batch | 4,365 | 347 | 34 | 311 |
| 2023 / 5th batch | 3,671 | 261 | 16 | 292 |
| 2024 / 6th batch | 3,012 | 136 | 7 | 342 |
| 2025 / 7th batch | 3,461 | 203 | 7 | 274 |
Counts come from public company records in the portal database.
Batch Trend by Segment
The trend compares the current industry across national, provincial and city samples by recognition batch.
National industryShandongChina
National peak: 2024 / 6th batch. Province peak: 2022 / 4th batch. City peak: 2021 / 3rd batch.
| Batch | National industry | Province segment | City segment | Province share |
|---|---|---|---|---|
| 2019 / 1st batch | 32 | 2 | 0 | 6.2% |
| 2020 / 2nd batch | 276 | 15 | 1 | 5.4% |
| 2021 / 3rd batch | 214 | 15 | 3 | 7.0% |
| 2022 / 4th batch | 311 | 29 | 2 | 9.3% |
| 2023 / 5th batch | 292 | 25 | 0 | 8.6% |
| 2024 / 6th batch | 342 | 10 | 0 | 2.9% |
| 2025 / 7th batch | 274 | 16 | 1 | 5.8% |
Counts use public recognition-batch records in the company database.
Industry Concentration Map
Province and city rankings show where the same industry is concentrated in the Little Giant database.
Province ranking
246
164
158
147
112
112
103
83
City ranking
| Rank | Region | Companies | Share |
|---|---|---|---|
| 1 | Beijing / Beijing | 160 | 9.3% |
| 2 | Shanghai / Shanghai | 145 | 8.4% |
| 3 | Shenzhen / Shenzhen | 112 | 6.5% |
| 4 | Jiangsu / Suzhou | 88 | 5.1% |
| 5 | Zhejiang / Hangzhou | 77 | 4.5% |
| 6 | Guangdong / Guangzhou | 73 | 4.2% |
| 7 | Hubei / Wuhan | 45 | 2.6% |
| 8 | Shandong | 7 | 0.4% |
Counts use the portal company database and the current industry label.
Report Snapshot
| Company | Shandong Nuominkang Pharmaceutical Research Institute Co., Ltd. |
| Region | Shandong |
| Industry | Biomedicine |
| Published | 2026-06-14 |
| Chinese report | Open Chinese report |